The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/Background-The potential health benefits of ω-3 polyunsaturated fatty acids (PUFAs) usually are studied using a combination of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). This combination reduces vulnerability to experimentally induced atrial fibrillation (AF). It is unknown whether EPA and DHA have differential effects when taken alone. Using a model of pacing-induced atrial hemodynamic overload, we investigated the individual effects of EPA and DHA on vulnerability to AF and atrial remodeling. Methods and Results-Thirty-four dogs were randomized into 3 groups, all of which underwent simultaneous atrial and ventricular pacing at 220 beats per minute for 14 days. One group received purified DHA (≈1 g/d) orally for 21 days beginning 7 days before pacing began. Similarly, 1 group received ≈1 g/d purified EPA. In a third (control) group (No-PUFAs), 8 dogs received ≈1 g/d olive oil, and 12 were unsupplemented. Electrophysiological and echocardiographic measurements were taken at baseline and 21 days. Atrial tissue samples were collected at 21 days for histological and molecular analyses. Persistent AF inducibility was significantly reduced by DHA compared with No-PUFAs median [25-75 percentiles], 0% [0%-3%] for DHA versus 3.1% [2.2%-11%] for No-PUFAs; P=0.007) but not by EPA (3.4% [1.9%-8.9%]). DHA also reduced atrial fibrosis compared with No-PUFAs (11±6% versus 20±4%, respectively; P<0.05), whereas EPA did not (15±5%; P>0.05). Conclusions-DHA is more effective than EPA in attenuating AF vulnerability and atrial remodeling in structural remodeling-induced AF. (Circ Arrhythm Electrophysiol. 2012;5:978-983.)
A trial fibrillation (AF) is the most common arrhythmia seen clinically, and its prevalence is increasing. 1 It is associated with significant morbidity and an elevated risk of death, primarily from stroke. 2 Current treatments (cardioversion, antiarrhythmic drugs, ablation) are limited in their efficacy. 3 
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The marine-derived n-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) may have beneficial effects in the treatment of AF. 4, 5 However, almost all studies of AF, and other disease states, have tested the effects of EPA and DHA in combination. Although similar, DHA and EPA have a different length, shape, distribution, and metabolic fate. 6 Many studies have shown differential effects of DHA and EPA on cardiovascular end points, such as hemodynamics, heart rate, endothelial function, and lipid status. 6, 7 However, EPA and DHA have been studied little in models of AF outside of postcardiac surgery AF.
The simultaneous atrial and ventricular pacing model (SAVP) results in substantial structural remodeling of the atria and vulnerability to AF. 8 We have shown previously that a fixed combination of DHA and EPA is effective in reducing atrial remodeling and inducible AF in this model. 9, 10 In the current study, we investigated the effect of purified DHA and purified EPA separately on vulnerability to AF in the SAVP model. We hypothesized that DHA would be more effective than EPA because of its higher concentration in heart tissue phospholipids. 11 1. Paced 14 days, no PUFAs (n=20) 2. Paced 14 days, DHA 21 days (n=8) 3. Paced 14 days, EPA 21 days (n=6) All groups underwent pacemaker implantation surgery and end study after 21 days, including echocardiographic and electrophysiological measurements. Details of surgical procedures, sample collection, and preparation are available in the online-only Data Supplement. Beginning 7 days before the start of pacing, 8 dogs from group 1 were given 2.5 mL/d olive oil (Filippo Berio Extra Virgin, San Migliarino, Italy) with no DHA and EPA, and the rest were not supplemented. Dogs in group 2 were given 2.7 mL/d purified DHA (yielding ≈1000 mg DHA; DHASCO, Martek Biosciences Corporation, Columbia, MD). Dogs in group 3 were given 2.5 mL/d purified EPA (yielding ≈1078 mg EPA; O3mega+ Joy, Genuine Health, Toronto, ON).
Results for group 1 (paced control) have been previously reported and are presented here to place the DHA and EPA groups in their proper context. 10
Surgical Procedures
Thirty minutes before the pacemaker implant procedure, or the 21day end study, dogs were sedated with intramuscular acepromazine (Atrovet, 0.05 mg/kg; Ayerst Veterinary Laboratories, Guelph, ON), atropine (0.03 mg/kg; Alveda Pharmaceuticals Inc, Bellville, ON), and buprenorphine (Temgesic, 0.02 mg/kg; Schering-Plough, Kirkland, QC). Anesthesia was induced with intravenous thiopental sodium (5% solution 0.25 mL/kg; Hospira Healthcare Corp, Saint-Laurent, QC) for pacemaker implant or intravenous propofol (Diprivan, 2.5-3.5 mg/kg; AstraZeneca, Mississauga, ON) for the 21-day study. Anesthesia was maintained with isoflurane (1%-2%; Halocarbon Products Corporation, River Edge, NJ). Deep anesthesia was confirmed by noting the absence of spontaneous breathing and absence of jaw tonus. During the 21-day study, while still under deep anesthesia, the dogs were killed by rapid excision of the heart.
Electrophysiological Study
Five bipolar, stainless steel, epicardial pacing/recording electrodes were sutured onto the heart at the right atrium appendage, left atrial appendage (LAA), high right atrial (superior vena cava), low right atrium (inferior vena cava), and pulmonary veins. Atrial effective refractory period was determined via the S1-S2 stimulus technique at a 200-ms cycle length. Conduction time between the LAA and the superior vena cava was calculated at a 400-ms cycle length and presented as a measure of global atrial conduction time. AF inducibility was measured via burst pacing at up to 5 electrodes (up to 10 bursts at each electrode). An AF incident was defined as any irregular atrial tachyarrhythmia that lasted ≥120 seconds, with atrial rate >300 beats per minute and resistant to pace termination; persistent AF was defined as an AF incident that lasted ≥600 seconds (10 minutes).
PUFA Isolation and Quantification
EPA and DHA levels were measured separately in plasma and atrial tissue samples by gas-liquid chromatography, as performed by Chen et al. 12
Atrial Electrophysiology
AF was defined as any irregular atrial tachyarrhythmia (atrial rate >300 beats per minute) with a duration ≥120 seconds and resistant to pace termination. Global atrial conduction time was calculated as mean conduction time between the superior vena cava and the left atrial LAA. Atrial effective refractory period was measured via the S1-S2 stimulus technique and was defined as the longest S1-S2 interval not resulting in atrial capture.
Cardiac Function (Echocardiography)
Transthoracic and transesophageal echocardiographic measurements were taken preoperatively in anesthetized dogs lying on their right side. During the 21-day study, the pacemaker was turned off at least 15 minutes before measurement.
Histology
All histological analyses were performed in a blinded fashion as described in Ref. 10 . Atrial fibrosis was quantified by analysis of picrosirius red-stained images of LAA tissue analyzed at ×10 magnification (20-30 images per dog). Each image was analyzed with a thresholding function to calculate the fraction of pixels containing collagen. To ensure accuracy, each thresholded image was compared with the unedited original to make sure only collagen was included.
Mean atrial myocyte cross-sectional area was calculated from measurement of ≈150 hematoxylin and eosin-stained LAA cells at ×40, as previously published.
Statistical Analyses
To account for multiple attempts at inducing AF in each dog, AF inducibility was analyzed using a generalized estimating equation 
Results

PUFA Integration
DHA supplementation resulted in significantly higher levels of DHA in plasma phospholipids compared with unsupplemented dogs (4.3±1.4% versus 1.9±0.3%; P=0.004). DHA supplementation also increased DHA in atrial tissue phospholipids ( Figure 1) . Similarly, EPA-supplemented dogs had both greater plasma EPA levels than unsupplemented dogs (1.2±0.4% versus 0.5±0.3%; P=0.01) and greater atrial tissue EPA levels ( Figure 1 ).
Atrial Electrophysiology
Persistent AF could be induced with 3.1% (2.2%-11%) (median [25-75 percentiles]) of bursts in the No-PUFAs group (Fig ure 2) . Significantly fewer episodes of persistent AF were inducible in the DHA group (0% [0%-3%]; P=0.007 compared with the No-PUFAs group). In the EPA group, persistent AF was induced with 3.4% (1.9%-8.9%) of bursts (P=0.04 compared with the DHA group). When self-terminating episodes are included (≥2 minutes but <10 minutes), AF could be induced with 7.3% (2.7%-15%) of all bursts in the No-PUFAs group (P=0.11 compared with the DHA group). In the EPA group, AF was induced with 5.6% (3.2%-18%) of bursts (P=0.16 compared with the DHA group). AF was induced in the DHA group with 1.3% (0%-7.7%) of bursts. The median number of attempts at inducing AF was 37 (30-43), 40 (34-40), and 30 (21-43) for the No-PUFAs, DHA, and EPA groups, respectively (P>0.05 for comparisons). The median number of AF incidents induced per dog was 3 (1-4), 0.5 (0-2.5), and 2 (0.8-3.5) for the No-PUFAs, DHA, and EPA groups, respectively (P>0.05 for comparisons). The median number of persistent AF episodes per dog was 1 (1-3), 0 (0-1), and 1 (0.8-1.5) for the No-PUFAs, DHA, and EPA groups, respectively (P=0.02 No-PUFAs versus DHA) (see online-only Data Supplement  Table SI ). Neither DHA nor EPA affected atrial conduction time or atrial effective refractory period (Table 1 ).
Cardiac Function
The increase in atrial systolic and diastolic volumes caused by SAVP between baseline and 21 days was significantly smaller in the DHA group compared with the No-PUFAs group (Figure 3 ; P=0.02 for left atrial systolic volume; P=0.04 for left atrial diastolic volume). The change in atrial volume was not affected by EPA (P=0.7 for both left atrial systolic volume and left atrial diastolic volume). Neither DHA nor EPA affected ventricular function ( 
Atrial Fibrosis
Treatment with DHA significantly reduced atrial collagen area fraction compared with the No-PUFAs group (11±6% versus 20±4%, respectively; P=0.004; Figure 4 ). Treatment with EPA did not affect fibrosis (15±5%; P=0.08).
Atrial Cellular Hypertrophy
Neither DHA nor EPA significantly affected the increase in atrial myocyte cross-sectional area induced by 14 days of SAVP (218±19 μm 2 , 171±15 μm 2 , 177±14 μm 2 for No-PUFAs, DHA, EPA, respectively; P=0.08 for No-PUFAs versus DHA; P=0.1 for No-PUFAs versus EPA).
Discussion
DHA, but not EPA, reduced vulnerability to persistent AF caused by 14 days of simultaneous atrial and ventricular pacing. DHA also reduced the atrial enlargement and fibrosis that resulted from pacing; EPA did not have a significant effect. Our previous work suggested that PUFAs (DHA+EPA) may attenuate AF vulnerability by retarding the development of arrhythmogenic structural changes in the atria (inflammation, hypertrophy, and fibrosis) brought on by pacing. 10, 13 The current study suggests that DHA is the more beneficial of the 2 components.
PUFA Integration
Compared with controls, 21 days of supplementation resulted in significantly higher levels of DHA in DHA-supplemented dogs and EPA in EPA-supplemented dogs, in both plasma and tissue. This suggests that both DHA and EPA were available in circulating and cardiomyocyte-bound forms. A potential limitation of prior studies with PUFA supplementation is that not enough lead time was allowed for sufficiently high PUFA concentrations to be achieved to produce the desired effect. Greater levels of DHA were seen in cardiac tissue than EPA (regardless of supplementation), consistent with observations by others that DHA is accumulated in the heart, whereas EPA is thought to accumulate in plasma. 14 The levels of integration observed in this study are comparable with other studies of PUFA supplementation in dogs. 15 Had we supplemented for a longer duration it is likely that there would have been a small increase in PUFA levels. 15 It is notable that DHA supplementation increased plasma EPA, possibly indicative of retroconversion of DHA to EPA; this also has been observed previously. 16
Observations of the DHA Effect in Other Studies
Although no other studies have tested DHA and EPA separately in a model of structural remodeling-induced AF, DHA is correlated with reduced incidence of AF in other models. In a rabbit study, Ninio et al 17 found that a DHA-enriched diet led to lower AF inducibility and maintenance. Kumar et al 18 showed that serum DHA, but not EPA, was associated with lower inducibility of AF in a study of 61 patients without known AF and no structural heart disease. The same investigator showed similar results with AF recurrence after cardioversion in a study of 178 patients with persistent AF. 19 A recent publication from the Cardiovascular Health Study observed that plasma DHA, but not EPA, was correlated with lower AF incidence in a cohort of more than 3000 elderly Americans. 20 Similarly, Kirkegaard et al 21 found that plasma DHA, but not EPA, was associated with a lower incidence of AF in 300 hemodialysis patients with cardiovascular disease. Data from 2174 middle-aged men in the Kuopio ischemic heart disease risk factor study showed that serum DHA, but not EPA, was significantly inversely correlated with risk of AF. 22
Possible Mechanisms for the DHA Effect
DHA and EPA are multipotent and putatively biologically active in a wide variety of areas, from cardiac function to mental health to skin elasticity. 23, 24 Although they are similar, they differ in chain length and number of double bonds (DHA has 2 more carbons and 1 more double bond). As such, they can have different interactions with receptors and enzymes and produce different metabolites. 25 Given that DHA is more abundant in cardiac tissue, it is potentially more likely to have cardiac effects than EPA. Our group showed that AF inducibility in the SAVP model is correlated with increasing hypertrophy and fibrosis, which may be triggered by early inflammation. 10 In an in vitro model, De Caterina et al 26 showed that DHA was more efficient than EPA in reducing inflammation. In addition, certain products of DHA metabolism (D-series resolvins) have been shown to have anti-inflammatory properties. 27 DHA-mediated suppression of atrial inflammation could be a potential explanation for the results seen in the current study. Previous work also has shown that PUFAs alter the tissue response to injury at the genetic level. 13 DHA, but not EPA, has been shown to be a ligand for nuclear receptors, including FXR and RXR, thus possibly affecting gene transcription. 25, 28 Other observed differences in DHA and EPA activity that may explain our observations include the ability of DHA, but not EPA, to block certain cardiac ion channels, especially repolarizing potassium channels or membraneincorporated DHA-mediated inhibition of cardiac adrenergic stimulation. 11, 29 Although these effects have been observed by others, we did not observe a PUFA effect on repolarization. A key to understanding the mechanism of the DHA effect may lie in the observation that DHA lowered the burden of persistent AF but not AF induction. This may suggest that DHA is effective in reducing factors that perpetuate AF, eg, anatomic heterogeneities, such as fibrosis, rather than factors leading to AF induction, eg, repolarization heterogeneities. 30, 31 Limitations This is an animal study with measurements taken only at baseline and after 14 days of SAVP. Structural remodeling 
Conclusion
Supplementation with DHA, but not EPA, reduces arrhythmogenic structural changes to the atria resulting from SAVP. 
CLINICAL PERSPECTIVE
ω-3 Polyunsaturated fatty acids (PUFAs) have been extensively studied for the prevention of atrial fibrillation. We and others have shown that the beneficial action of PUFAs in animal models of atrial fibrillation primarily results from the effects of PUFAs in preventing adverse atrial remodeling resulting from atrial mechanical stress. Prior studies of PUFAs have tested fixed combinations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (the PUFAs believed to be most important in reducing atrial remodeling), generally using a larger proportion of EPA. In this animal model of inducible atrial fibrillation, we show that the benefit of PUFAs largely resides in the DHA and not the EPA component. DHA alone prevented adverse atrial remodeling and atrial fibrillation inducibility, whereas EPA had minimal to no effect. This study suggests that if PUFAs are to be tested for their potential benefits in atrial fibrillation, DHA alone or a sufficiently high ratio of DHA to EPA should be used.
